Edge Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$76M Buy
1,142,575
+112
+0% +$7.46K 0.57% 62
2016
Q4
$74.6M Buy
1,142,463
+219,693
+24% +$14.3M 0.58% 61
2016
Q3
$65.3M Buy
922,770
+10,155
+1% +$740K 0.55% 58
2016
Q2
$67.5M Buy
912,615
+39,028
+4% +$2.7M 0.6% 53
2016
Q1
$56.7M Sell
873,587
-24,943
-3% -$1.7M 0.54% 57
2015
Q4
$69.3M Buy
898,530
+63,289
+8% +$5.03M 0.67% 48
2015
Q3
$68.8M Sell
835,241
-656
-0.1% -$58.4K 0.69% 50
2015
Q2
$73.7M Buy
835,897
+2,313
+0.3% +$212K 0.67% 47
2015
Q1
$73.7M Sell
833,584
-124,264
-13% -$11M 0.64% 51
2014
Q4
$79.5M Sell
957,848
-23,851
-2% -$1.98M 0.77% 42
2014
Q3
$82.8M Sell
981,699
-41,404
-4% -$3.35M 0.83% 40
2014
Q2
$83M Buy
1,023,103
+29,221
+3% +$2.3M 0.83% 39
2014
Q1
$75.7M Sell
993,882
-3,599
-0.4% -$262K 0.8% 42
2013
Q4
$71.8M Sell
997,481
-16,627
-2% -$1.16M 0.78% 44
2013
Q3
$69.7M Sell
1,014,108
-6,797
-0.7% -$450K 0.83% 42
2013
Q2
$64.7M Buy
+1,020,905
New +$66.4M 0.81% 43

Other funds holding NVS

Edge Asset Management's NVS Position: Q1 2017 in Review

Edge Asset Management increased its Novartis (NVS) stake by 0.01% in Q1 2017, buying an estimated $7.46K and bringing the position to 1,142,575 shares worth $76M. The position accounts for 0.57% of the portfolio, ranked #62.

Edge Asset Management first reported a position in NVS in Q2 2013 and has held it in 16 quarters since. The position peaked at $83M in Q2 2014. 910 funds tracked by Wall St. Rank hold NVS as of Q1 2017.

  • Edge Asset Management held 1,142,575 shares of Novartis worth $76M as of Q1 2017.
  • Edge Asset Management bought 112 Novartis shares in Q1 2017, an estimated $7.46K.
  • Novartis made up 0.57% of Edge Asset Management's portfolio in Q1 2017, its #62 holding.
  • Edge Asset Management first reported a position in Novartis in Q2 2013 and has held it in 16 quarters since.
  • Edge Asset Management's Novartis position peaked at $83M in Q2 2014.
  • 910 funds tracked by Wall St. Rank held Novartis as of Q1 2017.

Based on Edge Asset Management's 13F filing for Q1 2017, filed 11 May 2017.